Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of CM338 in Healthy Subjects
NCT05186285Phase 1Completed
- Sponsor
- Keymed Biosciences
- Start
- Dec 2021
- Primary completion
- Jul 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CM338 in IgA nephropathy (IgAN) (9 arms), sponsored by Keymed Biosciences. Primary endpoint: Incidence of Adverse Events at Day 57. Started Dec 2021; status: completed.
02
Drugs
CM338
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05186285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05186285.